Corning Announces Significant Milestone in High-Throughput Label-Free Screening for Drug Development
News Jun 13, 2008
Corning Incorporated has announced the completion of two independent high-throughput label-free screens believed to be the largest ever publicly announced label-free screens to date.
Scientists from two of the top 10 pharmaceutical companies each screened 100,000 drug candidates in high throughput using the label-free Corning® Epic® System. These two screens represent a major milestone in accelerating drug discovery using label-free technology.
“Our customers have demonstrated true high-throughput label-free screening – a goal that has eluded label-free researchers for many years,” said Ron Verkleeren, Epic business director, Corning Incorporated.
“Removing fluorescent, luminescent and radioactive labels from assays promises to improve the speed and quality of the drug discovery process,” he continued. “It can open up a wider variety of drug targets and enable researchers to study drug candidates in more physiologically relevant systems. These screens exemplify the remarkable progress label-free technology has made in the last few years and the significant impact it can have in the future.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE